Ataraxis AI develops clinical AI tools for cancer prognosis and treatment selection. Its Ataraxis Breast platform analyzes patient data to assess recurrence risk and treatment response.
Nebius named Ataraxis AI the biotechnology winner of its inaugural AI Discovery Awards in June 2025. Category winners received $100,000 in GPU credits for Nebius AI Cloud. VAST Data subsequently reported that Ataraxis AI was deploying the awarded resources for cancer diagnostics.
Nebius announces AI Discovery Awards winners23 Jun 2025 · Nebius · Web pageNebius names Ataraxis AI its biotechnology category winner and states that category winners receive $100,000 in Nebius AI Cloud GPU credits.
VAST Data reports deployment by award winners
25 Jun 2025 · VAST Data · Web page
VAST Data reports Ataraxis AI deploying GPU resources awarded by Nebius for cancer diagnostics.
VAST Data reports deployment by award winners25 Jun 2025 · VAST Data · Web pageVAST Data reports Ataraxis AI deploying GPU resources awarded by Nebius for cancer diagnostics.
Ataraxis AI develops clinical artificial intelligence tools that help oncologists assess cancer prognosis and select treatments. Its Ataraxis Breast platform analyzes digital pathology images and clinical information to estimate recurrence risk, individualized chemotherapy benefit and response to neoadjuvant therapy. The platform includes RISK, CTX and NEO tools for breast cancer care. Its underlying pathology foundation models extract information about tumor characteristics from slide images, supporting predictions of patient outcomes and treatment response. The company also collaborates with cancer centers on clinical validation.
Ataraxis reports NEO validation across breast cancer cohorts and clinical trials
Ataraxis reported that its NEO model predicted neoadjuvant therapy response in 1,412 patients across nine independent cohorts. Additional evaluations used 689 patients from the PHERGain and PHERGain-2 trials.
Ataraxis publishes Tau chemotherapy-benefit validation results
Ataraxis reported three clinical validation studies covering 18,426 patients, including analyses of the TAILORx and UNIRAD Phase 3 trials. It also reported that Tau transferred outcome and treatment-benefit predictions to additional cancer types without retraining.
Ataraxis launches ARC prospective oncology outcomes study
Ataraxis launched a prospective registry linking AI test predictions with patient outcomes. ARC initially targets approximately 1,000 patients enrolled over roughly two years, with follow-up lasting up to 10 years per participant.
Clinical AI company developing cancer prognosis and treatment-selection tools. · Health
How they use Nebius AI Cloud
Ataraxis AI develops clinical AI tools for cancer prognosis and treatment selection. Its Ataraxis Breast platform analyzes patient data to assess recurrence risk and treatment response.
Nebius named Ataraxis AI the biotechnology winner of its inaugural AI Discovery Awards in June 2025. Category winners received $100,000 in GPU credits for Nebius AI Cloud. VAST Data subsequently reported that Ataraxis AI was deploying the awarded resources for cancer diagnostics.
Nebius announces AI Discovery Awards winners23 Jun 2025 · Nebius · Web pageNebius names Ataraxis AI its biotechnology category winner and states that category winners receive $100,000 in Nebius AI Cloud GPU credits.
VAST Data reports deployment by award winners
25 Jun 2025 · VAST Data · Web page
VAST Data reports Ataraxis AI deploying GPU resources awarded by Nebius for cancer diagnostics.
VAST Data reports deployment by award winners25 Jun 2025 · VAST Data · Web pageVAST Data reports Ataraxis AI deploying GPU resources awarded by Nebius for cancer diagnostics.
Ataraxis AI develops clinical artificial intelligence tools that help oncologists assess cancer prognosis and select treatments. Its Ataraxis Breast platform analyzes digital pathology images and clinical information to estimate recurrence risk, individualized chemotherapy benefit and response to neoadjuvant therapy. The platform includes RISK, CTX and NEO tools for breast cancer care. Its underlying pathology foundation models extract information about tumor characteristics from slide images, supporting predictions of patient outcomes and treatment response. The company also collaborates with cancer centers on clinical validation.
Ataraxis reports NEO validation across breast cancer cohorts and clinical trials
Ataraxis reported that its NEO model predicted neoadjuvant therapy response in 1,412 patients across nine independent cohorts. Additional evaluations used 689 patients from the PHERGain and PHERGain-2 trials.
Ataraxis publishes Tau chemotherapy-benefit validation results
Ataraxis reported three clinical validation studies covering 18,426 patients, including analyses of the TAILORx and UNIRAD Phase 3 trials. It also reported that Tau transferred outcome and treatment-benefit predictions to additional cancer types without retraining.
Ataraxis launches ARC prospective oncology outcomes study
Ataraxis launched a prospective registry linking AI test predictions with patient outcomes. ARC initially targets approximately 1,000 patients enrolled over roughly two years, with follow-up lasting up to 10 years per participant.
